News
Pfizer Canada and BioNTech Receive Health Canada Approval of LP.8.1 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) "BioNTech" announced today that Health Canada has authorized the LP.8.1 ...
Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...
Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...
22h
Investor's Business Daily on MSNBioNTech ADR Meets 80-Plus Relative Strength Rating Benchmark
BioNTech ADR earns the No. 143 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals ...
11d
The Punch on MSNPfizer, BioNTech to pay CureVac, GSK $740m Covid jab settlement
American pharmaceutical giant Pfizer and German biotech firm BioNTech will pay Britain's GSK and Germany's CureVac $740 ...
The chapter on Pfizer and BioNTech’s mRNA patent feud with Germany’s CureVac is coming to a close, even as lawsuits over the ...
The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...
Recent developments have highlighted a major mRNA patent settlement involving BioNTech (BNTX) and CureVac, leading to a $370 million payment with GSK plc, which has added complexity to BioNTech's ...
BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...
“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...
GSK and CureVac will together receive $740 million, as well as royalties on sales of COVID-19 vaccines in the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results